Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial-Reference-Cited by-同舟云学术

Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial

Published:2017-10 Issue:10 Volume:27 Page:378-385
ISSN:1744-6872
Container-title:Pharmacogenetics and Genomics
language:en
Short-container-title:

Author:

Serie Daniel J.,Crook Julia E.,Necela Brian M.,Dockter Travis J.,Wang Xue,Asmann Yan W.,Fairweather DeLisa,Bruno Katelyn A.,Colon-Otero Gerardo,Perez Edith A.,Thompson E. Aubrey,Norton Nadine

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Genetics(clinical),Genetics,Molecular Biology,Molecular Medicine,General Pharmacology, Toxicology and Pharmaceutics

Reference47 articles.

1. Time- and dose-dependent changes in ejection fraction after anthracycline therapy;Narahara;J Cardiovasc Pharmacol,1979

2. Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial;Advani;J Clin Oncol,2016

3. ErbB2 is essential in the prevention of dilated cardiomyopathy;Crone;Nat Med,2002

4. Essential roles of Her2/erbB2 in cardiac development and function;Negro;Recent Prog Horm Res,2004

5. Dilated cardiomyopathy: the complexity of a diverse genetic architecture;Hershberger;Nat Rev Cardiol,2013

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meta-analysis of genome-wide association studies for cancer therapy-related cardiovascular dysfunction and functional mapping highlight an intergenic region close to TP63;Scientific Reports;2024-08-08

2. Genetic factors in the pathogenesis of cardio-oncology;Journal of Translational Medicine;2024-08-05

3. HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients;Clinical and Translational Oncology;2024-05-21

4. Harnessing iPSCs to Dissect Causality in Anthracycline-Induced Cardiotoxicity;JACC: CardioOncology;2024-02

5. Racial Disparity in Anthracycline-induced Cardiotoxicity in Breast Cancer Patients;Biomedicines;2023-08-17